Identifying the targets of protective immunity to severe falciparum malaria

确定严重恶性疟疾的保护性免疫目标

• 批准号: 10893666
• 负责人: Jonathan D. Kurtis
• 金额: $ 50.01万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-04 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10893666
• 关键词: Age; Ambulatory Care Facilities; Antibodies; Antibody Response; Antigen Targeting; Antigens; Aotus primate; Binding; Biological Assay; Blocking Antibodies; Blood; Calcium; Case/Control Studies; Caspase; Cell Death; Cells; Cerebral Malaria; Child; Complement; Complement Activation; DNA Fragmentation; Data; Disease; Encapsulated; Enrollment; Evaluation; Falciparum Malaria; Future; Glutamic Acid; Goals; Growth; Hospitals; Human; Immune; Immune Sera; Immunity; Immunologic Epidemiology; In Vitro; Individual; Infant; Investigation; Kenya; Libraries; Lipids; Malaria; Malaria Vaccines; Measures; Membrane; Messenger RNA; Mitochondria; Modeling; Morphology; Mus; Nature; Nuclear; Orthologous Gene; Parasitemia; Parasites; Phage Display; Phagocytosis; Phase; Phase I Clinical Trials; Plasma; Plasmodium falciparum; Predisposition; Proteins; Proteome; Resistance; Resistance development; Site; Surface; Vaccination; Vaccines; Work; antibody test; candidate selection; cohort; comparison control; design; innovation; nonhuman primate; novel; novel vaccines; polyclonal antibody; response; screening; vaccine candidate; vaccine trial

ABSTRACT The goal of this R01 application is to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and to develop them as novel blood-stage vaccine candidates. Of the ~100 malaria vaccine candidates currently under investigation, more than 60% are based on only four parasite antigens and the most advanced vaccine, RTS,S, generates only modest protection 1, 2. In previous studies, we developed a highly innovative whole proteome differential screening strategy which identifies the subset of parasite antigens that are recognized by antibodies expressed by resistant individuals but not susceptible individuals. Using this strategy, we discovered Schizont Egress Antigen-1 (PfSEA-1), a 244-kDa parasite antigen that is the target of antibodies which arrest parasites at the schizont stage and are associated with significant protection from severe malarial disease in a cohort of n=785 two yr old children. This is the first demonstration that antibodies that specifically block egress can protect against severe malaria in humans (Science 4). In parallel studies, we also identified PfGARP, a previously unrecognized vaccine candidate which localized to the exofacial surface of the RBC membrane in trophozoite infected RBC. Antibodies to the highly invariant carboxyl terminal of PfGARP (PfGARP-A, aa 411-673) inhibit parasite growth in vitro by 99% compared to controls (P < 0.001) by killing trophozoite stage parasites. Numerous mechanistic assays demonstrated that the binding of anti-PfGARP to the surface of the infected RBC induces parasite programed cell death as evidenced by pyknotic nuclear morphology, caspase activation, mitochondrial depolarization, DNA fragmentation, and release of intracellular calcium. In addition, vaccination of non-human primates with PfGARP formulated as a lipid encapsulated mRNA results in significant protection from P. falciparum challenge compared to controls (Nature 5). These preliminary results were based on differential screening using sera from resistant and susceptible individuals with the definition of resistance based solely on parasitemia. Previous work has demonstrated that children develop resistance to severe malaria after only one or two episodes, and this protection is distinct from responses that simply control parasitemia 6. In the current proposal, we will capitalize on this observation to identify parasite antigens that are targets of antibody responses which are acquired and expressed during the convalescent phase of an episode of severe malaria and protect against future episodes of severe malaria. We will: 1) conduct a case-control study at our field site in a holoendemic region of western Kenya to identify infants and children with severe malaria and matched controls. 2) perform whole proteome differential screening using sera from this case-control study, and 3) down select candidates for follow-on vaccine studies using a suite of assays (growth inhibition, human immunoepidemiologic studies, and murine vaccine trials).

摘要